Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NVS vs AZN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NVS Captures Overall Composite Edge (41.5 SELL vs 42.6 HOLD), While AZN Leads 3–2 on Growth & Valuation Pillars

NVS Overall Winner 6-Pillar Tally: NVS 2 – 3 AZN (1 Tie) Matrix Metrics: NVS 6 – 3 AZN

As of Nov 16, 2026, Novartis AG (NVS) captures the overall head-to-head institutional edge over AstraZeneca PLC (AZN) on higher Unified Composite conviction (41.5/100 SELL vs. 42.6/100 HOLD) after splitting the core matrix 6–3 (led by Profitability & Quality, Balance Sheet & Cash Flow), while AZN wins 3–2 across the 6-pillar growth and valuation breakdown. NVS trades at $161.59 (16.2x Forward P/E, 34.0% operating margin) versus AZN at $184.92 (16.3x Forward P/E, 25.8% operating margin).

  • Composite vs. Pillar Nuance: While AZN currently prints a higher short-term Unified Composite Score (42.6/100 HOLD vs. NVS 41.5/100 SELL), NVS captures the overall institutional head-to-head verdict (6–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 25.8% operating margin) and revenue trajectory (+4.7% vs. +6.7% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NVS vs AZN
NVS NYSE Head-to-Head Winner
Novartis AG
Pharmaceutical Preparations
$161.59
+0.68% 1D
Market Cap $302.9B
TTM Revenue $40.5B
Forward P/E 16.2x
Beta / 30D Vol 0.31β · 27% Vol
Unified Composite Score
41.5 / 100 SELL
Tech 29.0 Fund 38.0 Flow 50.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 61
RSI-14: 60.8 · SMA20: $159.19 · SMA50: $149.17
AZN NASDAQ
AstraZeneca PLC
Pharmaceutical Preparations
$184.92
+0.25% 1D
Market Cap $286.0B
TTM Revenue $62.4B
Forward P/E 16.3x
Beta / 30D Vol 0.03β · 32% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 24.0 Fund 39.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.4% over 20 days), RSI 63
RSI-14: 63.0 · SMA20: $180.12 · SMA50: $169.26

6-Pillar Scorecard Institutional Category Breakdown (NVS 2 – 3 AZN)

Columns: Metric · NVS · AZN
1. Valuation Multiples AZN
Forward P/E 16.2x 16.3x
Trailing P/E 30.6x 26.1x
PEG Ratio 3.81x 1.34x
EV / Revenue 7.5x 4.6x
2. Growth & Scale AZN
Revenue Growth (YoY) +4.7% +6.7%
Earnings Growth (YoY) -68.8% +23.5%
TTM Revenue (USD) $40.5B $62.4B
Market Cap $302.9B $286.0B
3. Profitability & Quality NVS
Gross Margin 75.2% 81.8%
Operating Margin 34.0% 25.8%
Net Profit Margin 17.5% 17.7%
Return on Equity (ROE) 24.3% 22.6%
4. Balance Sheet & Cash Flow NVS
Cash Generation (TTM) $17.0B EBITDA $21.3B EBITDA
Cash Flow Margin 42.0% EBITDA Mgn 34.1% EBITDA Mgn
Net Cash / Leverage $19.71 Book/Sh · 24.3% ROE $33.35 Book/Sh · 22.6% ROE
Dividend Yield 2.96% 1.74%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 16.9% (6th %ile) 20.3% (8th %ile)
Put/Call OI Skew Thin ADR Chain Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat AZN
OpEx & R&D Intensity 41.2% of Rev ($16.7B) 56.0% of Rev ($34.9B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Drug Manufacturers - General Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NVS (6) vs AZN (3)
Institutional Metric NVS AZN Criterion Row Edge
Market Capitalization
Scale
$302.9B $286.0B Larger Scale NVS
Trailing P/E Ratio
Valuation
30.6x 26.1x Lower Multiple AZN
Forward P/E Ratio
Valuation
16.2x 16.3x Lower Multiple NVS
Revenue Growth (YoY)
Growth
+4.7% +6.7% Higher Growth AZN
Operating Margin (TTM)
Profitability
34.0% 25.8% Higher Margin NVS
Net Profit Margin
Profitability
17.5% 17.7% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
24.3% 22.6% Higher ROE NVS
52-Week Range Position
Momentum
81% ($123–$170) 53% ($153–$213) Stronger Trend NVS
Beta / 30D Volatility
Risk Regime
0.31β · 27% Vol 0.03β · 32% Vol Lower Realized Risk NVS
Unified Institutional Score
Composite Signal
41.5 / 100 (SELL) 42.6 / 100 (HOLD) Higher Composite AZN
Trailing 12M Revenue (USD)
Operating Scale
$40.5B $62.4B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.2% 81.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.81x PEG · 7.5x EV/Rev 1.34x PEG · 4.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17.0B EBITDA ($19.71 Book/Sh · 24.3% ROE) $21.3B EBITDA ($33.35 Book/Sh · 22.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AZN +4.51 pp
NVS: +7.28% · AZN: +11.79%
3M Horizon AZN +10.94 pp
NVS: +4.56% · AZN: +15.5%
6M Horizon NVS +7.8 pp
NVS: +8.34% · AZN: +0.54%
1Y Horizon NVS +18.16 pp
NVS: +22.5% · AZN: +4.34%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs AZN. Trailing 12-month operating profitability (NVS 34.0% vs AZN 25.8%) and valuation multiples (NVS 16.2x vs AZN 16.3x Forward P/E) are benchmarked directly in Pillar 4 below.

NVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40.5B
Gross Margin75.2%
Op. Margin34.0%
ROE / Fwd P/E24.3% · 16.2x
AZN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$62.4B
Gross Margin81.8%
Op. Margin25.8%
ROE / Fwd P/E22.6% · 16.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NVS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 16.9%
IV Percentile 6th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AZN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 20.3%
IV Percentile 8th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NVS Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $302.9B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($16.7B)
90D Engineering Disclosures 0 Published
AZN Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $286.0B market capitalization and 25.8% operating margin.
OpEx & R&D Reinvestment 56.0% of Rev ($34.9B)
90D Engineering Disclosures 0 Published

Investor FAQ NVS vs AZN Key Questions & Quantitative Answers

As of Nov 16, 2026, Novartis AG (NVS) captures the overall head-to-head institutional edge over AstraZeneca PLC (AZN) on higher Unified Composite conviction (41.5/100 SELL vs. 42.6/100 HOLD) after splitting the core matrix 6–3 (led by Profitability & Quality, Balance Sheet & Cash Flow), while AZN wins 3–2 across the 6-pillar growth and valuation breakdown. NVS trades at $161.59 (16.2x Forward P/E, 34.0% operating margin) versus AZN at $184.92 (16.3x Forward P/E, 25.8% operating margin). Composite vs. Pillar Nuance: While AZN currently prints a higher short-term Unified Composite Score (42.6/100 HOLD vs. NVS 41.5/100 SELL), NVS captures the overall institutional head-to-head verdict (6–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 25.8% operating margin) and revenue trajectory (+4.7% vs. +6.7% YoY).

AZN leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with AZN at +6.7% YoY revenue growth and +23.5% YoY earnings growth on $62.4B TTM revenue (81.8% gross margin, 25.8% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $62.4B for AZN. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus 56.0% of Rev ($34.9B) (0 disclosures) for AZN.

AZN screens cheaper on headline valuation multiples. NVS trades at 16.2x Forward P/E, 30.6x Trailing P/E, 3.81x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas AZN trades at 16.3x Forward P/E, 26.1x Trailing P/E, 1.34x PEG, and 4.6x EV/Revenue (34.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus AZN (22.6% ROE) capital efficiency.

In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk). By comparison, AZN carries 20.3% implied volatility (8th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.03β · 32% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.